Overview
This study is to investigate whether the alternating use of Prolia (Denosumab) and Aclasta (Zoledronic acid) can continue to increase bone density.
Description
This study intends to use a randomized trial to test whether the long-term treatment of Denosumab and Zoledronic acid can achieve sustained bone density progress and avoid the risk of rapid bone loss after the withdrawal of Denosumab.
Eligibility
Inclusion Criteria:
- Postmenopausal women or men over 50 years old
- Denosumab treatment for at least two years and less than three years (up to five doses).
Exclusion Criteria:
- . Estimated glomerular filtration rate <35 ml/min.
- Malignancy
- Continuous steroid treatment, hormone therapy or other medical treatment affecting bone metabolism
- Secondary osteoporosis
- Metabolic bone diseases
- Contraindications to ZOL
- Patients older than 80 years old
- Hypocalcemia